Want to see FR:ALGAE full AI Analyst Report?
ALGAE Stock Chart & Stats
€0.43
-€0.01(-2.61%)
At close: 4:00 PM EST
€0.43
-€0.01(-2.61%)
Day’s Range― - ―
52-Week Range€0.40 - €0.64
Previous CloseN/A
Volume250.73K
Average Volume (3M)224.33K
Market Cap
€61.09M
Enterprise Value€44.32M
Total Cash (Recent Filing)€6.62M
Total Debt (Recent Filing)€5.02M
Price to Earnings (P/E)―
Beta0.95
Next Earnings
Oct 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding119,939,200
10 Day Avg. Volume242,064
30 Day Avg. Volume224,333
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)1.78
Price to Sales (P/S)3.34
P/FCF Ratio-5.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.08
Revenue Forecast (FY)€19.55M
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthSustained multi-year top-line growth demonstrates traction across end markets and supports scale options. A growing revenue base increases the potential to spread fixed bioprocessing costs, improves negotiating leverage with suppliers, and underpins longer-term margin improvement if growth persists.
Improving Unit EconomicsTransition to a positive gross margin signals improving production efficiency and/or better commercial mix. This structural improvement in core unit economics is a prerequisite for sustainable profitability as the company scales, reducing the cash required per incremental euro of revenue.
Lower Financial LeverageMaterial reduction in leverage lowers bankruptcy and refinancing risk and preserves borrowing capacity. Manageable debt levels give the company flexibility to fund capex or working capital for scaling production without immediately increasing financial strain on operations.
Bears Say
Persistent Cash BurnOngoing negative operating cash flow and worsening free cash flow create a structural funding requirement. Over months this limits investment flexibility, increases reliance on external capital or dilution, and raises the probability that management must prioritize liquidity over R&D or commercial expansion.
Deep Losses And Negative ReturnsVery large net losses and deeply negative ROE indicate the business is not yet generating returns sufficient to preserve shareholder capital. Absent a credible and sustained path to positive operating margins, the company risks continued equity erosion and limited ability to attract long-term capital.
Modest Revenue ScaleDespite strong growth rates, the absolute revenue base is still small relative to the capital intensity of industrial bioprocessing. Limited scale constrains economies, keeps unit costs and overheads high, and makes achieving durable profitability and margin resilience more challenging without further material scale-up.
ALGAE FAQ
What was Fermentalg SA’s price range in the past 12 months?
Fermentalg SA lowest stock price was €0.40 and its highest was €0.64 in the past 12 months.
What is Fermentalg SA’s market cap?
Fermentalg SA’s market cap is €61.09M.
When is Fermentalg SA’s upcoming earnings report date?
Fermentalg SA’s upcoming earnings report date is Oct 06, 2026 which is in 93 days.
How were Fermentalg SA’s earnings last quarter?
Fermentalg SA released its earnings results on Apr 02, 2026. The company reported -€0.053 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.053.
Is Fermentalg SA overvalued?
According to Wall Street analysts Fermentalg SA’s price is currently Overvalued.
Does Fermentalg SA pay dividends?
Fermentalg SA does not currently pay dividends.
What is Fermentalg SA’s EPS estimate?
Fermentalg SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Fermentalg SA have?
Fermentalg SA has 119,939,200 shares outstanding.
What happened to Fermentalg SA’s price movement after its last earnings report?
Fermentalg SA reported an EPS of -€0.053 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.724%.
Which hedge fund is a major shareholder of Fermentalg SA?
Currently, no hedge funds are holding shares in FR:ALGAE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Fermentalg SA
Fermentalg SA, established in 2009 and headquartered in Libourne, France, is an internationally operating company specializing in the research, manufacturing, and sale of functional ingredients sourced from microalgae. These offerings serve various industries, including food, health, nutritional supplements, and environmental protection. Their product portfolio features DHA ORIGINS, a plant-derived DHA oil; KALVEA PLUS, a high-protein algal concentrate tailored for aquaculture feed; Everzure, a naturally occurring, acid-stable blue colorant; BLUE ORIGINS AOX, known for its antioxidant and anti-inflammatory benefits; BLUE ORIGIN, another natural coloring agent; and advanced clean air solutions designed for industrial CO2 capture.